The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT)
- PMID: 9562345
- PMCID: PMC2635092
- DOI: 10.1007/s001250050924
The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT)
Abstract
In the Diabetes Control and Complications Trial (DCCT), 1441 insulin-dependent diabetic patients in the primary prevention and secondary intervention cohorts were randomly assigned to either conventional or intensive therapy and followed for up to 9 years. Baseline and biennial measurements of autonomic function (R-R variation, Valsalva ratio, and postural testing) as well as quarterly assessment of autonomic symptoms were performed throughout the trial. There were no differences at baseline between patients randomized to intensive vs conventional therapy. In general, autonomic abnormalities increased during the trial; however, R-R variation was less abnormal in the intensively treated secondary intervention (7% with abnormal results at 4-6 years) compared with the conventionally treated group (14% with abnormal results, p = 0.004) and in the combined cohorts (5% of intensive treatment subjects with abnormal results vs 9% of conventional treatment subjects, p = 0.0017). There were few abnormal Valsalva ratios or postural tests at baseline or during the trial. No significant difference in Valsalva ratio or postural tests occurred between the intensive and conventional treatment groups. Both the R-R variation and the Valsalva ratio had significantly greater slopes of decline over time in the patients randomized to conventional therapy (1.48 points per year and 0.015 per year, respectively) compared to those randomized to intensive therapy (0.912 points per year and 0.0025 per year). Of the symptoms related to autonomic function, only incomplete bladder emptying was significantly more common in the conventional group. In summary, the DCCT documented that intensive therapy can slow the progression and the development of abnormal autonomic tests.
Figures
Similar articles
-
Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.Diabetes Care. 2014;37(1):31-8. doi: 10.2337/dc13-2114. Diabetes Care. 2014. PMID: 24356595 Free PMC article. Clinical Trial.
-
Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC).Circulation. 2009 Jun 9;119(22):2886-93. doi: 10.1161/CIRCULATIONAHA.108.837369. Epub 2009 May 26. Circulation. 2009. PMID: 19470886 Free PMC article. Clinical Trial.
-
The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.Diabetes. 1996 Oct;45(10):1289-98. Diabetes. 1996. PMID: 8826962 Clinical Trial.
-
Diabetic autonomic neuropathy.Diabetes Care. 2003 May;26(5):1553-79. doi: 10.2337/diacare.26.5.1553. Diabetes Care. 2003. PMID: 12716821 Review.
-
How to ameliorate the problem of hypoglycemia in intensive as well as nonintensive treatment of type 1 diabetes.Diabetes Care. 1999 Mar;22 Suppl 2:B43-52. Diabetes Care. 1999. PMID: 10097899 Review.
Cited by
-
Treatment-induced neuropathy of diabetes: an energy crisis?Brain. 2015 Jan;138(Pt 1):2-3. doi: 10.1093/brain/awu327. Brain. 2015. PMID: 25564488 Free PMC article.
-
Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.Diabetes Care. 2014;37(1):31-8. doi: 10.2337/dc13-2114. Diabetes Care. 2014. PMID: 24356595 Free PMC article. Clinical Trial.
-
Diabetic Gastroparesis: Principles and Current Trends in Management.Diabetes Ther. 2018 Jul;9(Suppl 1):1-42. doi: 10.1007/s13300-018-0454-9. Epub 2018 Jun 22. Diabetes Ther. 2018. PMID: 29934758 Free PMC article. Review.
-
Cardiovascular autonomic neuropathy is associated with macrovascular risk factors in type 2 diabetes: new technology used for routine large-scale screening adds new insight.J Diabetes Sci Technol. 2014 Jul;8(4):874-80. doi: 10.1177/1932296814528616. Epub 2014 Mar 31. J Diabetes Sci Technol. 2014. PMID: 24876410 Free PMC article.
-
The Role of Biofactors in Diabetic Microvascular Complications.Curr Diabetes Rev. 2022;18(4):e250821195830. doi: 10.2174/1871527320666210825112240. Curr Diabetes Rev. 2022. PMID: 34433401 Free PMC article.
References
-
- The DCCT Research Group. The effect of intensive treatment of diabetes on the development of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. - PubMed
-
- The DCCT Research Group. The effect of intensive treatment of diabetes therapy on the development and progression of neuropathy. Annals Int Med. 1995;122:561–568. - PubMed
-
- Reichard P, Nilsson BY, Rosenquist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304–309. - PubMed
-
- Mogensen CE. Autonomic and somatosensory nerve function after 2 years of continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes. 1988;37:452–455. - PubMed
-
- Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Int Med. 1991;230:101–108. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical